Verve Therapeutics (VERV)
(Delayed Data from NSDQ)
$6.31 USD
-0.42 (-6.24%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $6.31 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Verve Therapeutics (VERV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$25.78 | $40.00 | $15.00 | 283.06% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Verve Therapeutics comes to $25.78. The forecasts range from a low of $15.00 to a high of $40.00. The average price target represents an increase of 283.06% from the last closing price of $6.73.
Analyst Price Targets (9 )
Broker Rating
Verve Therapeutics currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 8.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/VERV.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/9/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
4/8/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Not Available | Strong Buy |
4/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/2/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
4/2/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
2/28/2024 | LifeSci Capital | Cory Jubinville | Strong Buy | Strong Buy |
2/28/2024 | Cantor Fitzgerald & Co | Rick Bienkowski | Hold | Hold |
12/1/2023 | Goldman Sachs | Andrea Tan | Strong Sell | Strong Sell |
10/23/2023 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 12 |
Average Target Price | $25.78 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 154 of 253 |
Current Quarter EPS Est: | -0.68 |